These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33661174)

  • 1. Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.
    Shen D; Song H; Zhang J; Liao C; Wang Y; Fang M; Tang Y
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e1-e4. PubMed ID: 33661174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
    Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
    Kim D; Koh Y; Yoon SS
    Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
    Bossi E; Aroldi A; Brioschi FA; Steidl C; Baretta S; Renso R; Verga L; Fontana D; Sharma GG; Mologni L; Mussolin L; Piazza R; Gambacorti-Passerini C
    Am J Hematol; 2020 Dec; 95(12):E319-E321. PubMed ID: 32808682
    [No Abstract]   [Full Text] [Related]  

  • 6. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
    Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
    Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.
    Tomlinson SB; Sandwell S; Chuang ST; Johnson MD; Vates GE; Reagan PM
    Leuk Res; 2019 Aug; 83():106164. PubMed ID: 31226541
    [No Abstract]   [Full Text] [Related]  

  • 9. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers.
    Jerry L; Swan L; Dana N; Balis FM; Greengard E; Huiping X
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31139. PubMed ID: 38867367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observation of Alectinib- and Crizotinib- included chemotherapy in children with ALK-positive anaplastic large cell lymphoma: A single institutional experience.
    He Y; Pei K; Zhang H; Wang J; Su X; Gan W; Wang P
    Cancer Med; 2023 Mar; 12(6):7182-7188. PubMed ID: 36408869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma.
    Rigaud C; Abbou S; Minard-Colin V; Geoerger B; Scoazec JY; Vassal G; Jaff N; Heuberger L; Valteau-Couanet D; Brugieres L
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29193772
    [No Abstract]   [Full Text] [Related]  

  • 15. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.
    Reed DR; Hall RD; Gentzler RD; Volodin L; Douvas MG; Portell CA
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e247-e250. PubMed ID: 30992232
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib.
    Sakamoto H; Yanagitani N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Yoshida H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Tasaka S; Nishio M
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1414. PubMed ID: 33960745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
    Brugières L; Cozic N; Houot R; Rigaud C; Sibon D; Arfi-Rouche J; Bories P; Cottereau AS; Delmer A; Ducassou S; Garnier N; Lamant L; Leruste A; Millot F; Moalla S; Morschhauser F; Nolla M; Pagnier A; Reguerre Y; Renaud L; Schmitt A; Simonin M; Verschuur A; Hoog Labouret N; Mahier Ait Oukhatar C; Vassal G
    Eur J Cancer; 2023 Sep; 191():112984. PubMed ID: 37549532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.